Skip to main content

Table 3 Ongoing phase III trials with targeted agents in advanced gastric cancer

From: Targeted and novel therapy in advanced gastric cancer

Targeted pathway Agent/selection biomarker Trial design identifier
HER Varlitinib/HER1 and HER2 Phase II/III 1st-line comparing varlitinib plus mFOLFOX6 versus placebo plus mFOLFOX6 NCT03130790
Nimotuzumab/HER1 ENRICH 2nd-line comparing irinotecan with or without nimotuzumab in Asian patients NCT01813253
Angiogenesis Ramucirumab/HER2(−) ARMANI comparing maintenance therapy with ramucirumab plus paclitaxel versus continuation of 1st-line chemotherapy NCT02934464
Regorafenib/none INTEGRATEII 3rd-line comparing regorafenib versus placebo NCT02773524
Apatinib/none ANGEL 3rd-line comparing apatinib versus placebo NCT03042611
Fruquintinib/none FRUTIGA 2nd-line comparing fruquintinib plus paclitaxel versus placebo plus paclitaxel  NCT03223376
Anlotinib/none ALTER0503 3rd-line comparing anlotinib versus placebo NCT02461407
PD-1/PD-L1 Nivolumab with or without ipilimumab/HER2(−) CheckMate649 1st-line comparing nivolumab plus ipilimumab or nivolumab plus chemotherapy against chemotherapy alone NCT02872116
Nivolumab/HER2(−) ATTRACTION-4 1st-line comparing nivolumab plus chemotherapy versus placebo plus chemotherapy NCT02746796
Pembrolizumab/PD-L1 KEYNOTE-063 2nd-line comparing pembrolizumab versus paclitaxel in Asian patients NCT03019588
Pembrolizumab/HER2 KEYNOTE-811 1st-line comparing pembrolizumab plus trastuzumab in combination with chemotherapy versus placebo plus trastuzumab in combination with chemotherapy NCT03615326
Pembrolizumab/none KEYNOTE-590 1st-line in esophageal including gastroesophageal junction cancer comparing chemotherapy versus chemotherapy plus pembrolizumab in Chinese patients NCT03189719
Avelumab/HER2(−) JAVELIN Gastric 100 comparing maintenance therapy with avelumab versus continuation of 1st-line chemotherapy NCT02625610
FGFR2 FPA144/FGFR2 & HER2(−) FIGHT/1st-line comparing FPA144 plus mFOLFOX6 versus placebo plus mFOLFOX6 NCT03694522
Claudin 18.2 IMAB362/claudin 18.2 & HER2(−) SPOTLIGHT/1st-line comparing IMAB362 plus mFOLFOX6 versus placebo plus mFOLFOX6 NCT03504397
  1. HER human epidermal growth factor receptor, mFOLFOX6 5-fluorouracil/leucovorin/oxaliplatin, PD-1 programmed death-1, PD-L1 programmed death ligand 1, FGFR2 fibroblast growth factor receptor 2